What is the clinical significance of human herpesvirus‑6 (HHV‑6) infection?

Clinical Significance of HHV-6

HHV-6B is the most frequent infectious cause of encephalitis after allogeneic hematopoietic stem cell transplantation (HSCT) and is associated with increased mortality, acute graft-versus-host disease (GvHD), delayed engraftment, and CMV reactivation in immunocompromised patients 1.

Primary Clinical Contexts

In Immunocompromised Patients (Post-HSCT)

HHV-6B reactivation occurs in approximately 47-50% of allogeneic HSCT recipients 2, 3. The clinical significance in this population is substantial and multifaceted:

Encephalitis:

• Most critical manifestation with direct impact on mortality
• Presents as post-engraftment acute limbic encephalitis (PALE)
• Requires aggressive treatment with foscarnet (90 mg/kg twice daily) or ganciclovir (5 mg/kg twice daily) for at least 3 weeks 1
• Full-dose therapy (foscarnet ≥180 mg/kg or ganciclovir ≥10 mg/kg daily) achieves response rates of 93% and 84% respectively, significantly better than lower doses 1

Associated Complications:

• Grade II-IV acute GvHD: Meta-analysis demonstrates strong association (HR: 2.65; 95%CI: 1.89-3.72; P<0.001) 1
• All-cause mortality: Adjusted hazard ratio of 2.9 (95% CI: 1.1-7.5) 3
• Delayed engraftment: Lower probability of monocyte engraftment (adjusted HR: 0.42) and platelet engraftment (adjusted HR: 0.47) 3
• CMV reactivation: Increased risk through IL-12 inhibition and shared immunosuppression pathways 1

In Immunocompetent Individuals

Primary infection (HHV-6B):

• Causes exanthema subitum (roseola infantum) in young children
• Generally self-limited with favorable outcomes 4, 5
• Severe disease in immunocompetent adults is uncommon but documented, including disseminated infection with CNS involvement 6

Key Diagnostic Considerations

Critical pitfall: Chromosomally integrated HHV-6 (ciHHV-6) occurs when viral DNA integrates into germline chromosomes, resulting in persistent HHV-6 DNA detection in all nucleated cells 7. This condition:

• Affects approximately 1% of the population
• Confounds diagnosis of true reactivation
• Must be excluded in donor and recipient before attributing clinical significance to positive HHV-6 PCR 1
• Requires testing on hair follicles or multiple tissue types to distinguish from active infection

For diagnosing active disease:

• Quantitative PCR on plasma/serum for reactivation monitoring
• CSF PCR for encephalitis diagnosis
• Higher viral loads correlate with CNS dysfunction (HR: 21; 95% CI: 1.8-249) 3
• RNA-based tests (in situ hybridization or RT-PCR for mRNA) demonstrate active replication 1

Management Approach

Prevention

Routine screening and prophylaxis are NOT recommended 1:

• HHV-6 DNA screening in blood post-HSCT: Not recommended (DIIu)
• Prophylactic or pre-emptive antiviral therapy: Not recommended (DIIu)
• Prophylactic foscarnet and pre-emptive ganciclovir trials failed to reduce encephalitis incidence, likely due to inadequate CNS penetration

Treatment Indications

Treat only documented end-organ disease, particularly encephalitis 1:

First-line options:

• Foscarnet 90 mg/kg IV twice daily (preferred if renal function permits)
• Ganciclovir 5 mg/kg IV twice daily (preferred if bone marrow suppression is a concern)
• Duration: Minimum 3 weeks and until HHV-6 DNA clears from blood and CSF 1
• Reduce immunosuppression when possible (BIII recommendation) 1

Drug selection rationale:

• Foscarnet: Nephrotoxic but no myelosuppression
• Ganciclovir: Myelosuppressive but less nephrotoxic
• Both have proven efficacy; choice depends on patient comorbidities 1
• Combination therapy achieved 100% response in small series but increases toxicity risk 1

Emerging Therapies

• Adoptive immunotherapy with virus-specific T cells shows promise in small studies but remains investigational 1
• Brincidofovir has activity but significant GI toxicity limits use 1

Contemporary Considerations

The landscape is evolving with newer cellular therapies 2, 8:

• Post-transplant cyclophosphamide use
• Letermovir for CMV prophylaxis (may indirectly affect HHV-6 epidemiology)
• CAR-T cell therapy recipients (epidemiology and significance still being defined)

For end-organ diseases other than encephalitis: Insufficient data exist to make treatment recommendations 1. The causal relationship between HHV-6 detection and manifestations like pneumonitis, hepatitis, or bone marrow suppression remains unclear.